| Authors: |
Drakaki A; Division of Hematology and Oncology, UCLA David Geffen School of Medicine, Los Angeles, California., Powles T; Barts Cancer Centre, Barts Health NHS Trust, Queen Mary University of London, London, United Kingdom., Bamias A; National and Kapodistrian University of Athens, Athens, Greece., Martin-Liberal J; Medical Oncology Department, Catalan Institute of Oncology (ICO) Hospitalet, Barcelona, Spain., Shin SJ; Yonsei Cancer Center, Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea., Friedlander T; University of California San Francisco, Helen Diller Family Cancer Center, San Francisco, California., Tosi D; Institut régional du Cancer de Montpellier (ICM), Montpellier, France., Park C; Norton Cancer Institute, Louisville, Kentucky., Gomez-Roca C; Department of Medical Oncology, Institut Claudius Regaud/IUCT Oncopole, Toulouse, France., Joly Lobbedez F; Centre Francois-Baclesse, Medical Oncology, Caen, France., Castellano D; Hospital 12 de Octubre, Madrid, Spain., Morales-Barrera R; Vall d'Hebron Institute of Oncology, Vall d' Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain., Moreno-Candilejo I; START Madrid Phase I Unit, Hospital Sanchinarro, Madrid, Spain., Fléchon A; Centre Léon Bérard, Lyon, France., Yuen K; Genentech, Inc., South San Francisco, California., Rishipathak D; Genentech, Inc., South San Francisco, California., DuPree K; Genentech, Inc., South San Francisco, California., Young F; Roche Products Ltd, Welwyn Garden City, United Kingdom., Michielin F; Roche Innovation Center Basel, Basel, Switzerland., Shemesh CS; Genentech, Inc., South San Francisco, California., Steinberg EE; Genentech, Inc., South San Francisco, California., Williams P; Genentech, Inc., South San Francisco, California., Lee JL; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. |
